Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ArcticZymes Technologies Board/Management Information 2017

Sep 12, 2017

3538_rns_2017-09-12_4c24422b-df0d-4ac3-a357-6dd9afd55154.html

Board/Management Information

Open in viewer

Opens in your device viewer

Biotec Pharmacon appoints new CEO

Biotec Pharmacon appoints new CEO

(Tromsø 12. September 2017) Biotec Pharmacon ASA (OSE:BIOTEC) is pleased to

announce that the company has hired Mr. Christian Jørgensen as the new CEO of

Biotec Pharmacon ASA.

Christian has a MBA from INSEAD and MSc. Econ. from the University of

Copenhagen. He has extensive background from the global healthcare industry,

with positions as General Manager for Baxter Healthcare in Western Europe,

Executive Vice President at Coloplast and President for Hill-Rom's European

business.

Christian will commence in his position on 2 October 2017 and Svein Lien will

resign from his position as of the same date, and become available as a

consultant for a period going forward.

"After Svein decided to resign as a CEO, the Board has thoroughly searched the

Norwegian and the international market for suitable candidates to take the helm

of Biotec. We are therefore very pleased to announce Christian Jørgensen, who is

a very experienced international leader of several biotech companies, as the new

CEO. We are confident that Christian will preserve and develop Biotec Phamacon's

commercial opportunities further and to be a key driver of strategic initiatives

that will enhance shareholder value going forward. I would also like to use this

opportunity to thank Svein Lien for his efforts to build Biotec Pharmacon to

become a valued player in the advanced enzyme business and to build a broad

platform of opportunities with the beta-glucan technology. ", says Erik Thorsen,

Chairman of the Board in Biotec Pharmacon ASA.

For additional information:

Erik Thorsen

Chairman of the Board

+47 907 56 685

[email protected]

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics.